DCC INDIA

Conference Programme

Day One - Friday, July 25, 2008
08.00	Registration and Tea
08.45	Inaugural Session and Presentation by Chief Guest Dr. K.K. Tripathi, Senior Advisor, Dept. of Biotechnology, Govt. of India.
09.20	Keynote Presentation by The Chairperson Leveraging India's offshoring potential in CRAMS Dr. Ajit Dangi, President & CEO, Danssen Consulting, former Director General, OPPI. (Click Here to View the Profile)
09.55	Indian Govt regulatory IP and patent protection Dr. Gopakumar G Nair, IPR Consultants & Advisors, Gopakumar Nair Associates. (Click Here to View the Profile)
10.30	Tea and Biscuits
Drug Discovery , Development and Technologies Sessions
10.50	Global Drug Discovery Partnerships From Technologies to Therapies From Contract delivery to Specialty pharma In and Out-licensing drug discovery research Drug Delivery technologies as tools for product lifecycle management Dr. Swaminathan Subramaniam, MD, PhD, Head of Indian Operations and Director of Business Development, Rheoscience – India (Click Here to View the Profile)
11.30	Bio-Pharma Industry climbing the value chain Generics to Discovery Natural product based Drug Discovery Traditional knowledge lead molecules Entry of biosimilar products and bio-generic drugs Patenting issues in biopharmaceutical areas Dr. Jitendra Malik, Ph.D, Attorney at Law, Alston & Bird LLP (Click Here to View the Profile)
12.10	Cancer Discovery and Development 15 years of Cancer Clinical Trials in India Prof (Dr) Purvish M Parikh, MD, DNB, FICP, PhD, ECMO, CPI, MBA, Medical Oncologist & Hematologist, Founder Convener, INdian Co-operative Oncology Network, Mumbai, India (Click Here to View the Profile)
12.50	Evolving environment for Pharmacovigilance and Risk Management Assessing the development of methodologies for monitoring drug safety Implementing Risk Management plans Practical applications and experiences of adopting a risk management plan Dr. Pipasha Biswas, MD, MPM, DM, MRQA, FRSM, Founder, Symogen, UK (Click Here to View the Profile)


13.10 To 14.10 Lunch Session
Contract Research & Manufacturing Sessions
14.10	Building Clinical Trial Infrastructure Dr. Aparna Parikh, MD, DCH, CCRA, Director - Scientific Affairs, PRA International (Click Here to View the Profile)
14.50	Managing Successfully clinical trials
15.30	Conducting phase II and III clinical trials in India - Challenges and Opportunities Dr. Munish Mehra, PhD., Managing Director, Global Drug Development Experts, Washington (Click Here to View the Profile)
16.10	Tea and Biscuits
16.20	Seamless Trial Design and Adaptive Clinical Trials Ms. Parminder Kaur, European Regulatory Leader, Octoplus N.V. Netherlands (Click Here to View the Profile)
17.00	Cancer Testing in India From an outsourcing prospective for global players Vivek Trikha, Head diagnostics, Dabur OncQuest (Click Here to View the Profile)
17.50	Panel Discussion - Challenges in the Evolving Pharmacovigilance Environment and Risk Management Dr. Pipasha Biswas, Founder Symogen, UK Dr. Vivek Ahuja, Ranbaxy Laboratories Dr. Moin Don, Johnson & Johnson Dr. Dhananjay Bakhle, Reliance LifeScience
18.30	Cocktail Networking

Day Two - Saturday, July 26, 2008
08.00	Registration and Tea
08.45	Keynote Presentation by the Chairperson Drug Development: Government Support for Quality Research Dr. B. M. Gandhi CEO, Neo Biomed Services, Former Advisor, Department of Biotechnology, Govt. Of India (Click Here to View the Profile)
09.15	Achieving process efficiency in Biopharmaceutical manufacturing Dr. Eric Grund, Ph.D., Director, Fast Trak Biopharma Services, GE Life Sciences (Click Here to View the Profile)
09.45	Role of Indian Biotech parks for the rapid development of biotechnology related business and research in India Anil C Ghosh, Adviser, Biotechnology, Government of Assam, Director & Vice Chairman, Chemgen Pharma International Pvt Ltd (Click Here to View the Profile)
10.15	Drug development challenges faced by developing biotech and pharmaceutical companies Harjit Singh, Senior Development Manager (Clinical Research), Takeda Pharmaceuticals (Click Here to View the Profile)
10.45	Tea and Biscuits
Contract Research and Manufacturing Sessions
11.00	What are the challenges for a pharmaceutical company to perform clinical trials in new unknown countries? Franois Simon Regional Head Clinical Monitoring International, Middle East, Africa, Asia , Pacific, Merck Serono International S.A. (Click Here to View the Profile)
11.30	CRO in India-Cost or Quality? Dr. Mary Francis, Director, Jovis Clinical Research and Dean cum Director, ICTCR (International Center for Training in Clinical Research). (Click Here to View the Profile)
12.00	Setting up a Signal Detection Unit in a Global generic company – Challenges & Experiences Dr. Vivek Ahuja, Associate Director, Ranbaxy Laboratories Ltd (Click Here to View the Profile)
12.30	Nurturing Biotechnology need for IP protection Hari Krishna Maram, Director – Strategic Initiatives, VVN Institute of Management, Technology and Research (Click Here to View the Profile)

13.00 -14.00 Lunch Session
Drug Discovery & Development Sessions
14.00	Cardio-Metabolic Disease Drug Discovery and Development Developing New Therapeutics for the Treatment of Cardio- Metabolic diseases: Challenges and Opportunities New Drug Delivery Technologies Evaluate the limitations of existing therapies and exploring new advances and one in the pipeline Dr. K G RAJENDRAN Head-Knowledge Cell, USV Ltd
14.30	The Next Generation of Therapeutics: Emerging Biologics, Stem Cells and RNAi Next Generation Antibody Therapeutics and Antibody Fragments Stem Cell and RNAi Therapeutics Progressing to the Clinic Proteins, Peptides and other Targets for Drug Development Dr. Utpal Bhadra Ph.D., Group leader, CCMB, Wellcome Trust fellow, HFSP Investigator, Adjunc Faculty, ICRESAT, Centre for Cellular and Molecular Biology
15.00	New Technologies in Cervical Cancer Dr. Swati Bhattacharya, Vice President of Biology Solutions, Simbiosys Biowares Inc
15.30	Tea and Biscuits
15.40	Venture capital and Private equity investment for Life Science industry Funding for drug discovery and development VC Investment and M&A Scenario in India
16.10	Pharmacoassurance: Managing the Increased Complexity What it takes for a quality system to support the pharmacovigilance Compliance of shared products The structure required for Summary of Pharmacovigilance Systems Risk management and the challenges of a QP role Quality aspects to consider in contracts and what to prioritize
16.40	Panel Discussion - Clinical Research and Trials Outsourcing - Challenges and Hurdles – Non-Availability of patients Lack of hospital infrastructure Delay in Govt Regulatory approvals